✉ Email this page to a colleague
« Back to Dashboard
Resminostat is an investigational drug.
There have been 6 clinical trials for Resminostat. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Carcinoma, Sezary Syndrome, and Mycosis Fungoides. The leading clinical trial sponsors are 4SC AG, Yakult Honsha Co., LTD, and [disabled in preview].
Recent Clinical Trials for Resminostat
|A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat||4SC AG||Phase 1|
|Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)||4SC AG||Phase 2|
|Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)||Yakult Honsha Co., LTD||Phase 1/Phase 2|